Lion Biotechnologies Inc. (LBIO) Reaches New 1-Year High at $9.45
Lion Biotechnologies Inc. (NASDAQ:LBIO)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $9.45 and last traded at $8.93, with a volume of 439,439 shares trading hands. The stock had previously closed at $8.84.
Several brokerages have commented on LBIO. Roth Capital reiterated a “buy” rating and set a $15.00 price target on shares of Lion Biotechnologies in a report on Saturday, July 9th. Chardan Capital reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Saturday, June 4th. FBR & Co reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Tuesday, May 3rd. Zacks Investment Research upgraded Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Wednesday, May 4th. Finally, SunTrust Banks Inc. downgraded Lion Biotechnologies from a “buy” rating to a “neutral” rating and lowered their price target for the company from $37.00 to $30.50 in a report on Monday, June 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.17.
The company’s market cap is $421.43 million. The stock has a 50 day moving average of $8.18 and a 200 day moving average of $6.25.
Lion Biotechnologies (NASDAQ:LBIO) last issued its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Analysts expect that Lion Biotechnologies Inc. will post ($0.73) EPS for the current year.
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.